Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.21.2
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 13, 2021
Nov. 04, 2020
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]                          
Royalties payments   $ 20,000,000   $ 8,000,000                  
Due to licensor current       $ 8,000,000     $ 34,434,000     $ 34,434,000   $ 31,515,000  
License to be paid     $ 8,000,000                    
Interest payable                         $ 1,000,000
License termination date     May 02, 2020                    
Non-cash licensed technology impairment charge             $ 32,900,000 $ 32,916,000    
Amortization of intangible assets             $ 29,000 $ 44,000   58,000 $ 1,300,000    
Abeona Therapeutics LLC [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
Finite-lived intangible asset, useful life           20 years              
RDEB Product [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
Debt Instrument, Periodic Payment, Principal                   28,000,000      
Debt Instrument, Increase, Accrued Interest                   6,400,000      
Original License Agreement [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
License to be paid                         10,000,000
Eb Agreement [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
License to be paid                         3,000,000
Eb Agreement [Member] | Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1                          
Indefinite-lived Intangible Assets [Line Items]                          
License to be paid                         $ 8,000,000
REGENXBIO [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
Due remains value $ 28,000,000.0                 28,000,000      
Litigation Settlement, Amount Awarded from Other Party                   $ 18,000,000.0      
Licensing Agreements [Member] | REGENXBIO [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
Royalty fees         $ 180,000,000                
Royalties payments   $ 20,000,000     20,000,000                
Payment on execution of contracts         10,000,000                
Due to licensor current         10,000,000                
Milestone payment         $ 60,000,000                
Finite-lived intangible asset, useful life         8 years                
Loss contingency accrual                       8,000,000  
Payments for legal settlements                       $ 20,000,000  
Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]                          
Indefinite-lived Intangible Assets [Line Items]                          
Annual fees         $ 100,000,000